The Myasthenia Gravis Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Myasthenia Gravis Treatment Market:
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report
According to The Business Research Company’s Myasthenia Gravis Treatment Global Market Report 2024, The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, emergence of plasma exchange, patient advocacy.
The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, long-term safety monitoring.
The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care services and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2022, according to the data published by the National Organization for Rare Disorders, a US-based non-profit organization providing support for individuals with rare diseases, autoimmune myasthenia gravis had an estimated prevalence of 14–40 per 100,000 individuals in the United States. For instance, in December 2021, according to the study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia, the global prevalence of myasthenia gravis was estimated to be 12.4 people per 100,000 people. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp
The myasthenia gravis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses
Product innovations are a key trend gaining popularity in the myasthenia gravis treatment market. Major companies operating in the myasthenia gravis treatment market are focused on developing new solutions to sustain their position in the market. For example, in December 2021, Argenx SE, a Netherlands-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug VYVGARTô (efgartigimod alfa-fcab) for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis. With this approval, VYVGART has become the first and only FDA-approved neonatal Fc receptor (FcRn) blocker used for generalized myasthenia gravis treatment. The company has reached agreements in principle with several regional and national commercial payers to structure a value-based agreement, providing appropriate access for patients and predictability of cost for payers.
The myasthenia gravis treatment market report table of contents includes:
1. Executive Summary
2. Myasthenia Gravis Treatment Market Characteristics
3. Myasthenia Gravis Treatment Market Trends And Strategies
4. Myasthenia Gravis Treatment Market - Macro Economic Scenario
5. Global Myasthenia Gravis Treatment Market Size and Growth
.....
32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking
33. Global Myasthenia Gravis Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market
35. Myasthenia Gravis Treatment Market Future Outlook and Potential Analysis
36. Appendix
Related Reports
https://topprnews.com/print-label-market
https://topprnews.com/primary-school-market-size
https://topprnews.com/pressure-transducer-market
https://goodprnews.com/print-label-market
https://goodprnews.com/primary-school-market-size
https://goodprnews.com/pressure-transducer-market
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Myasthenia Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2027Overview:The latest study conducted by Market Research Future (MRFR) reveals the global myasthenia gravis (MG) is set to witness 9.61% CAGR during the assessment period (2018-2023) and surpass a valuation of USD 3,000 Mn.
In recent years, a sharp rise in MG and related incidences has been noticed.
It is understood that early diagnosis and treatment can reduce the impact of the condition to a significant extent, however outcomes may vary from case to case.Advances in technology has resulted in development of therapeutics that are more effective as compared to traditional medicines.
At the same time, increased level of awareness among patients and government support in product research & development is expected to create market opportunities in forthcoming years.
Nonetheless, high cost of treatment is currently viewed as the primary restraint for the markets Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7267Segmental AnalysisThe report includes a segmental analysis of the market, which covers disease type, end-user, diagnosis and treatment and region.
By end user, the market has been segmented into academic and research organizations, diagnostic centers and hospitals and clinics.
myasthenia gravis treatment Market Research Report: Diagnosis (Imaging, Blood Tests, Electrodiagnostic, Edrophonium Test), Treatment (Medication, Surgery, HSCT), End-User (Hospitals, Clinics, Academic Research Institutes) – Global Forecast Till 2023The myasthenia gravis treatment Market report offers insights into the leading market players and presents an assessment of their current market position.
Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M activities, and the latest R initiatives is also available in the reportMajor Key PlayersThe key strategies followed by the players operating in the global myasthenia gravis treatment Market were innovation, product development, acquisition, and expansion.Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India), F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius Kabi (Germany), and others.Market Segment AnalysisThe global myasthenia gravis treatment Market has been segmented on the basis of diagnosis, treatment, and end-user.On the basis of diagnosis, the global myasthenia gravis treatment Market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium test, pulmonary function test, and others.
The imaging segment is classified into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.On the basis of treatment, the global myasthenia gravis treatment Market can be segmented into medication, surgery, autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others.The medication segment is divided into acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others.
The acetylcholinesterase inhibitors are classified into atropine, neostigmine, pyridostigmine, and others.
The immunosuppressant drugs are further divided into prednisone, azathioprine, mycophenolate mofetil, tacrolimus, and rituximab.
The steroids are further divided into prednisone and others.
